All In Biotech

Drug Trial Radar · NCT01681940

Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis

A Multi-Center, Open-Label Trial of the Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis

Last checked: Nov 20, 2026Latest source record: Mar 29, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Jan 2012

Primary completion

Aug 2012

Study completion Sep 2013

Sponsor

Lead sponsor
Zymenex A/SIndustry
Sponsor type
Industry
Collaborators
European Commission
First posted
Sep 10, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 5 years, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall objective is to evaluate the long-term efficacy, safety and tolerability of repeated Lamazym i.v. treatment in patients 5-21 years of age with alpha-Mannosidosis

Conditions

  • Alpha-Mannosidosis

Interventions

  • LamazymDrug

    ERT, i.v. infusions weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction of Oligosaccharides in blood serumTime frame: 6 months

Locations

4 sites in 4 countries. Site status is shown where the registry gives one.

  • Kinderneurologie Metabole Ziekten, UZ Brussel, Laarbeeklaan 101

    Brussels, Belgium

  • Center for Metabolic Diseases, Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9

    Copenhagen, Denmark

  • Servicio de Pediatría, Hospital Materno Infantil, Reina Sofía, Avda Menéndez Pidal sn

    Córdoba, Spain

  • Genetic Medicine, 6th floor, St Mary's Hospital, Oxford Road,

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.